肝积方对不同临床病理分型肝癌NET1、CK19蛋白的影响  

Effect of Ganji Decoction on NET1 and CK19 Proteins in Different Clinicopathological Types of Hepatocellular Carcinoma

作　　者：陈铨栩 罗晓智 张普[1] 陈迪[2] CHEN Quanxu;LUO Xiaozhi;ZHANG Pu;CHEN Di(Department of Pathology,The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,Zhejiang,China;Department of Pharmacy,The Second Affiliated Hospital of Wenzhou Medical University,Wenzhou 325000,Zhejiang,China)

机构地区：[1]温州医科大学附属第二医院病理科,浙江温州325000 [2]温州医科大学附属第二医院药剂科,浙江温州325000

出　　处：《中华中医药学刊》2020年第12期123-127,共5页Chinese Archives of Traditional Chinese Medicine

基　　金：国家科技部科技基础性工作专项基金(2017FY8389673)。

摘　　要：目的探讨肝积方对不同临床病理分型肝癌患者NET1、CK19蛋白的影响。方法回顾2016年1月—2018年12月在医院诊断治疗的肝癌患者60例临床资料,肝细胞肝癌患者中22例采用肝动脉化疗栓塞治疗及手术治疗为肝细胞肝癌A组,23例在此基础上加用肝积方治疗,为肝细胞肝癌B组;肝内胆管癌患者中7例采用肝动脉化疗栓塞治疗及手术治疗为肝内胆管癌A组,8例采用在此基础上加用肝积方治疗,为肝内胆管癌B组。比较不同病理分型患者治疗前后Karnofsky评分,血清AFP、CEA水平,NET1、CK19蛋白阳性表达率及表达强度。结果 (1)治疗后各组Karnofsky评分较治疗前均显著升高,差异有统计学意义(P<0.05);治疗后,肝细胞癌B组Karnofsky评分显著高于肝细胞癌A组,肝内胆管癌B组Karnofsky评分显著高于肝内胆管癌A组,差异均有统计学意义(P<0.05)。(2)治疗后,各组AFP与CEA均显著低于治疗前,差异有统计学意义(P<0.05);治疗后肝细胞癌B组AFP与CEA显著低于肝细胞癌A组,肝内胆管癌B组显著低于肝内胆管癌A组,差异有统计学意义(P<0.05)。(3)治疗后,各组NET1阳性率以及阳性强度均显著低于治疗前,差异有统计学意义(P<0.05);治疗后,肝细胞癌B组NET1阳性率以及阳性强度显著低于肝细胞癌A组,差异有统计学意义(P<0.05)。(4)治疗后,肝内胆管癌A组与肝内胆管癌B组阳性强度均显著低于治疗前,差异有统计学意义(P<0.05)。结论肝积方用于辅助治疗不同病理分型肝癌患者,可显著改善患者生活质量,降低血清AFP、CEA水平,降低NET1阳性表达以及表达强度,可显著降低对肝内胆管癌CK19蛋白表达强度。Objective To discuss the effect of Ganji Decoction on NET1 and CK19 proteins in different clinicopathological types of hepatocellular carcinoma. Methods The clinical data of 60 patients with hepatocellular carcinoma diagnosed and treated in hospital from January 2016 to December 2018 was retrospectively reviewed. A total of 22 patients with hepatocellular carcinomatreated with transcatheter arterial chemoembolization(TACE) and surgery were as hepatocellular carcinoma group A. On this basis, 23 patients treated with Ganji Decoction were hepatocellular carcinoma group B. Seven patients with intrahepatic cholangiocarcinoma treated with transcatheter arterial chemoembolization and surgery were as intrahepatic cholangiocarcinoma group A. Eight cases were treated with Ganji Decoction on the basis of the above treatment were intrahepatic cholangiocarcinoma group B. Karnofsky score, serum levels of AFP and CEA, positive expression rate of NET1 and CK19 protein and expression intensity were compared before and after treatment in patients with different pathological types. Results(1)After treatment, Karnofsky scores of each group were significantly higher than those before treatment, and the difference was statistically significant(P<0.05). After treatment, the Karnofsky score of hepatocellular carcinoma group B was significantly higher than that of hepatocellular carcinoma group A. The Karnofsky score of intrahepatic cholangiocarcinoma group B was significantly higher than that of intrahepatic cholangiocarcinoma group A(P<0.05).(2) After treatment, AFP and CEA in each group were significantly lower than those before treatment(P<0.05). After treatment, AFP and CEA in hepatocellular carcinoma group B were significantly lower than those in hepatocellular carcinoma group A, and those in intrahepatic cholangiocarcinoma group B were significantly lower than those in intrahepatic cholangiocarcinoma group A(P<0.05).(3)After treatment, the positive rate and intensity of NET1 in each group were significantly lower than those before

关 键 词：肝积方 临床病理分型 肝癌 NET1 CK19蛋白 

分 类 号：R256.4[医药卫生—中医内科学]